Piperacillin (As Sodium) , Tazobactam (As Sodiuim) - نتائج البحث

الفلبين - الإنجليزية - FDA (Food And Drug Administration)

pzbactam 4 g/500 mg powder for iv injection

eon pharmatek inc.; distributor: eon pharmatek inc. - piperacillin (as sodium) , tazobactam (as sodium) - powder for iv injection - 4 g/500 mg

أستراليا - الإنجليزية - Department of Health (Therapeutic Goods Administration)

piptaz sandoz 4g/0.5g piperacillin (as sodium) 4g and tazobactam (as sodium) 0.5 g powder for injection bottle

sandoz pty ltd - piperacillin sodium, quantity: 4.253 g; tazobactam sodium, quantity: 0.547 g (equivalent: tazobactam, qty 0.5 g) - injection, powder for - excipient ingredients: - piptaz sandoz is used to treat serious bacterial infections caused by susceptible strains of beta-lactamase producing organisms in the conditions listed below: 1) lower respiratory tract infections; 2) urinary tract infections (complicated and uncomplicated); 3) intra-abdominal infections; 4) skin and skin structure infections; 5) bacterial septicaemia; 6) gynaecological infections. children under the age of 12 years: in hospitalised children aged 2 to 12 years, piptaz sandoz is indicated for the treatment of serious intra-abdominal infections. it has not been evaluated in children below the age of 2 years. while piptaz sandoz (piperacillin/tazobactam) is indicated only for the conditions listed above, it may be used as a single agent in the treatment of mixed infections caused by piperacillin susceptible and beta-lactamase producing, piperacillin-resistant organisms. appropriate culture and susceptibility tests should be performed before treatment in order to identify organisms causing infection to determine their susceptibility to piptaz sandoz (piperacillin/tazobactam). therapy with piptaz sandoz (piperacillin/tazobactam), however, may be initiated before results of each test are known when there is reason to believe the infection may involve any of the beta-lactamase producing organisms listed above, however, once these results are available, appropriate therapy should be continued. in serious infections, presumptive therapy with piptaz sandoz (piperacillin/tazobactam) may be initiated before susceptibility test results are available. combination therapy with piptaz sandoz (piperacillin/tazobactam) and aminoglycosides may be used int he treatment of serious infections caused by pseudomonas aeruginosa. both drugs shold be used in full therapeutic doses. as soon as results of culture and susceptibility tests become available, antimicrobial therapy should be adjusted.